Developing prevalence-based prescribing units for analysing variations in general practitioner prescribing: A case study using statins

Journal of Clinical Pharmacy and Therapeutics

Volumn 28, Issue 1, 2003, Pages 23-29

  Ward, Paul R ^a   Noyce, P R ^b   St Leger, A S ^b  

^a SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Prescribing units; Statins; Variations in prescribing

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG COST; FEMALE; GENERAL PRACTICE; GENERAL PRACTITIONER; HUMAN; INFANT; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NEWBORN; PRESCRIPTION; PREVALENCE; SEX RATIO; STATISTICAL ANALYSIS; UNITED KINGDOM;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; DRUG UTILIZATION; ENGLAND; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG; SEX FACTORS;

EID: 0037295218     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.2003.00451.x     Document Type: Article

References (25)

1. Shepherd J, Cobbe S, Ford E. (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. New England Journal of Medicine, 333, 1301-1307.
2. Downs JR, Clearfield M, Weis S et al. (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. Journal of the American Medical Association, 279, 1615-1622.
3. Scandinavian Simvastatin Survival Study Group. (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 344, 1383-1389.
4. Sacks FM, Pfeffer MA, Moye LA et al. (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. New England Journal of Medicine, 335, 1001-1009.
5. Department of Health (2000) National Service Frameworks for Coronary Heart Disease. London: Stationary Office.
6. Baxter C, Jones R, Corr L. (1998) Time trend analysis and variations in prescribing lipid lowering drugs in general practice. British Medical Journal, 317, 1134-1135.
7. Packham C, Robinson J, Morris J, Richards C, Marks P, Gray D. (1999) Statin prescribing in Nottingham general practices: a cross-sectional study. Journal of Public Health Medicine, 21, 60-64.
8. Packham C, Pearson J, Robinson J, Gray D. (2000) Use of statins in general practices, 1996-8: cross sectional Study. British Medical Journal, 320, 1583-1584.
9. Majeed A, Moser K, Maxwell R. (2000) Age, sex and practice variations in the use of statins in general practice in England and Wales. Journal of Public Health Medicine, 22, 275-279.
10. Whincup PH, Papacosta O, Walker M, Lennon L, Thomson A. (2001) Lipid lowering drug use in older British men with established coronary heart disease: evidence of underuse. Heart, 85(Suppl. 1), 5.
11. McPherson K. (1994) How should health policy be modified by the evidence of medical practice variations? In: Marinker M, ed. Controversies in Health Care Policies. London: BMJ Publishing Group, 55-74.
12. Roberts SJ, Harris CM. (1993) Age, sex, and temporary resident originated prescribing units (ASTRO-PUs): new weightings for analysing prescribing of general practices in England. British Medical Journal, 307, 485-488.
13. Lloyd DC, Harris CM, Roberts DJ. (1995) Specific therapeutic group age-sex related prescribing units (STAR-PUs): weightings for analysing general practices' prescribing in England. British Medical Journal, 311, 991-994.
14. Prescribing Support Unit. (2000) Average Daily Quantities and STAR(97)-PUs. Leeds: PSU.
15. Majeed A, Evans N, Head P (1997) What can PACT tell us about prescribing in general practice? British Medical Journal, 315, 1515-1519.
16. Chapman SR. (2001) Prescribing information systems; making sense of primary care data. Journal of Clinical Pharmacy and Therapeutics, 26, 235-239.
17. Bashford JN, Norwood J, Chapman SR. (1998) Why are patients prescribed proton pump inhibitors? Retrospective analysis of link between morbidity and prescribing in the General Practice Research Database. British Medical Journal, 317, 452-456.
18. Majeed A, Ferguson J, Field J. (1999) Prescribing of beta-2 agonists and inhaled steroids in England: trends between 1992 and 1998, and association with material deprivation, chronic illness and asthma mortality rates. Journal of Public Health Medicine, 21, 395-400.
19. Hollowell J. (1997) The General Practice Research Database: quality of morbidity data. Population Trends, 87, 36-40.
20. Office for National Statistics. (1998) Key Statistics from General Practice. Table 5C3: persons prescribed drugs in selected BNF categories per 1000 patients by age, sex and calendar year-1994-1998. London: ONS.
21. Office for National Statistics (1998) Key Statistics from General Practice. Table 6A1: prevalence of treated CHD per 1000 patients by age, sex and country/region-1994-1998. London: ONS.
22. Bogle SM, Harris CM. (1994) Measuring prescribing: the shortcomings of the item. British Medical Journal, 308, 637-640.
23. Walley T, Roberts DJ. (2000) Average daily quantities: a tool for measuring prescribing Volume in England. Pharmacoepidemiological Drug Safety, 9, 55-58.
24. Prescribing Support Unit. (1997) Defined Daily Doses, Prescribed Daily Doses and Average Daily Quantities. Leeds: Prescribing Support Unit.
25. Libby G, MacDonald TM, Evans JMM. (2001) Record-linkage methodology for prescribing research. Journal of Clinical Pharmacy and Therapeutics, 26, 241-246.